aTyr Pharma (NASDAQ:ATYR) Stock Rating Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of aTyr Pharma (NASDAQ:ATYR) to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings lowered shares of aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, September 16th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy”.

aTyr Pharma Price Performance

Shares of ATYR opened at $4.94 on Friday. aTyr Pharma has a 12 month low of $4.07 and a 12 month high of $44.40. The stock’s 50-day moving average is $13.21 and its two-hundred day moving average is $24.14. The stock has a market cap of $12.10 million, a PE ratio of -0.20 and a beta of 0.91.

aTyr Pharma (NASDAQ:ATYR) last posted its earnings results on Friday, August 7th. The company reported ($4.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.86) by $0.46. On average, research analysts anticipate that aTyr Pharma will post -17.80 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in aTyr Pharma stock. Renaissance Technologies LLC bought a new position in shares of aTyr Pharma, Inc. (NASDAQ:ATYR) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm bought 40,522 shares of the company’s stock, valued at approximately $32,000. Institutional investors and hedge funds own 61.72% of the company’s stock.

About aTyr Pharma

aTyr Pharma, Inc (NASDAQ:ATYR) is a biotechnology company focused on developing therapies that modulate immune system activity. The company’s research is based on a class of naturally occurring proteins known as extracellular tRNA synthetases, which can influence biological processes involved in inflammation, tissue repair and immune regulation.

aTyr’s lead product candidate is efzofitimod, an engineered protein therapeutic designed to target neuropilin-2 and regulate immune responses in the lungs.